4178 — StemCyte International Cashflow Statement
0.000.00%
Last trade - 00:00- TWD4.10bn
- TWD2.26bn
- TWD382.69m
Annual cashflow statement for StemCyte International, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -128 | -332 | -205 |
| Depreciation | |||
| Amortisation | |||
| Non-Cash Items | 13.8 | 175 | 28.1 |
| Discontinued Operations | |||
| Unusual Items | |||
| Equity in Net Earnings/Losses | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | 21.7 | 6.37 | -27.4 |
| Change in Accounts Receivable | |||
| Change in Inventories | |||
| Change in Prepaid Expenses | |||
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Other Liabilities | |||
| Other Operating Cash Flow | |||
| Cash from Operating Activities | -35.5 | -92.7 | -141 |
| Capital Expenditures | -5.47 | -5.61 | -31.4 |
| Purchase of Fixed Assets | |||
| Purchase / Acquisition of Intangibles | |||
| Other Investing Cash Flow Items | -78.1 | -99.9 | -187 |
| Acquisition of Business | |||
| Sale of Business | |||
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Sale of Intangible Assets | |||
| Other Investing Cash Flow | |||
| Cash from Investing Activities | -83.6 | -105 | -218 |
| Financing Cash Flow Items | 0 | 0.502 | -0.129 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | -30.1 | 787 | 1,174 |
| Foreign Exchange Effects | |||
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | -99.6 | 556 | 919 |